Highlight
1. In autoantibody-positive individuals with overweight or obesity, normalization of BMI is linked with a 48.4% reduced risk of developing stage 3 type 1 diabetes (T1D). 2. This protective association is predominantly observed in youth rather than adults. 3. BMI normalization reduces the risk of progression through multiple stages of T1D development, especially from stage 1 to stage 2 and stage 2 to stage 3. 4. Adjustments for insulin sensitivity attenuate the BMI effect, while insulin secretion and glycemia-adjusted markers reinforce it.
Study Background
Type 1 diabetes is characterized by autoimmune destruction of pancreatic beta cells, leading to insulin deficiency and hyperglycemia. Identifying modifiable risk factors to delay or prevent progression from asymptomatic autoimmunity to clinical diabetes is a critical research and public health priority. Elevated body mass index (BMI) is increasingly recognized as a risk enhancer for progression to clinical T1D among individuals positive for diabetes-related autoantibodies, possibly due to metabolic stress and insulin resistance. However, it remains unclear if BMI reduction could mitigate this risk, particularly in high-risk overweight or obese populations. The TrialNet Pathway to Prevention study provides a platform to investigate this clinically relevant question.
Study Design
This observational analysis included 833 autoantibody-positive individuals with overweight or obesity enrolled in the TrialNet Pathway to Prevention study. Participants were followed longitudinally with serial assessments for progression through defined stages of T1D: from stage 0 (autoantibody-negative) through stage 3 (clinical diagnosis). The primary endpoint was progression to stage 3 T1D. BMI changes over time were tracked, with normalization defined as a reduction from overweight/obese to normal BMI range. Statistical evaluation employed Cox proportional hazards models adjusted for baseline age, BMI z score, and T1D stage to assess the impact of BMI normalization on progression risk. Subgroup analyses by age and sex were performed, alongside exploratory models incorporating insulin sensitivity/resistance and beta cell function markers.
Key Findings
During a median 4.1 years follow-up, 26.8% of participants achieved BMI normalization. This was associated with a significant 48.4% reduction in risk of progressing to clinical stage 3 T1D (hazard ratio [HR] 0.516, P<0.001). Stratification revealed that this protective effect was primarily observed in youth (n=421; HR 0.497, P=0.001), including boys under 12 years (P<0.001) and girls aged 12 or older (P=0.043). In contrast, BMI normalization did not confer statistically significant risk reduction in adults (n=412, P=0.130).
BMI normalization was also linked with lower risk of transition from stage 1 to 2 (P=0.010) and from stage 2 to 3 (P=0.003), though the effect was less clear from stage 0 to 1 (P=0.051). These trends suggest that weight normalization may intervene effectively in later preclinical phases of disease.
Exploratory adjustments for metabolic factors revealed that controlling for insulin sensitivity/resistance indices or oral disposition index reduced the strength of the association between BMI normalization and progression risk, indicating that insulin resistance may mediate part of this relationship. Conversely, adjustments for insulin secretion, glycemia-adjusted C-peptide, or progression-risk indices strengthened the association, frame that BMI normalization’s benefit may also be independent of beta cell secretory capacity.
Expert Commentary
This study compellingly highlights the potential of BMI normalization as a modifiable factor that could delay progression to clinical T1D in high-risk youth with overweight or obesity. The findings align with the concept that insulin resistance and increased metabolic demand accelerate beta cell dysfunction in type 1 diabetes pathogenesis. While randomized controlled trials would be needed to establish causality, these observational data strongly support integrated strategies targeting weight management alongside immunological markers in preclinical T1D screening programs.
Limitations include the observational design, which cannot exclude residual confounding, and the lack of intervention-specific data. The differential impact by age underscores the need for age-tailored preventive interventions. Furthermore, the attenuation of the association upon adjusting for insulin sensitivity indices suggests metabolic pathways are key mediators, meriting further mechanistic research.
Conclusion
In summary, BMI normalization in autoantibody-positive individuals with overweight or obesity markedly lowers the risk of progression to clinical T1D, mainly in youth. These data emphasize the importance of early weight management and metabolic health optimization in reducing T1D incidence and suggest potential targets for future preventive clinical trials. Timely intervention in modifiable risk factors such as obesity offers a promising avenue to mitigate T1D burden in susceptible populations.
Funding and Clinical Trials Registry
This study was conducted under the TrialNet Pathway to Prevention study consortium. Funding sources and clinical trial registration details are available in the original publication (PMID: 42461847).
References
Redondo MJ, Cuthbertson D, Gupta R, et al. BMI Normalization Is Associated With Lower Risk of Progression to Type 1 Diabetes, Primarily in Youth. Diabetes Care. 2026 Jul 16. PMID: 42461847.
